Intravitreal injection versus medical treatment for acute CSR

Evaluation of the Effect of Intravitreal Anti-vascular Endothelial Growth Factor versus Medical Treatment in Acute Central Serous Chorioretinopathy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202204601902304

Enrollment

Registered

2022-04-14

Start date

2021-11-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eye Diseases

Interventions

Oral spironolactone

Intravitreal injection of Ranibizumab

Intravitreal injection of Aflibercept

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients older than 18 years old, with presence of serous detachment of neurosensory retina on optical coherence tomography angiography (OCTA), evidence of fluorescent leakage on fundus fluorescein angiography (FFA) and symptom duration less than 3 months will be enrolled in the study.

Exclusion criteria

Exclusion criteria: Patients with chronic CSCR, secondary choroidal neovascularization, other eye diseases such as AMD, polypoidal choroidal vasculopathy, glaucoma, or ocular trauma; or having history of systemic steroid usage before the onset of the clinical symptoms will be excluded from the study.

Design outcomes

Primary

Measure	Time frame
Visual recovery	—

Secondary

Measure	Time frame
Central macular thickness, central choroidal thickness, vascular density, pattern on flourescein angiography and duration of visual recovery	—

Countries

Egypt

Contacts

Public ContactMoataz Sallam

Lecturer at Faculty of Medicine Suez Canal University

Moataz.sallam@med.suez.edu.eg+201111113588

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026